TUESDAY, Feb. 14 (HealthDay News) -- Men and women who stayed on the experimental weight-loss drug rimonabant for two years managed to lose weight and keep it off, a new study finds. And as an added bonus, those using rimonabant also showed improved blood levels of cholesterol and triglycerides, the researchers report. Rimonabant, which will likely be marketed by drug maker Sanofi-Aventis as Accomplia, is currently under review by the U.S. Food and Drug Administration. If approved, it would become the third drug approved for weight loss, after orlistat (Xenical) and sibutramine (Meridia). "These are the longest results to date,"...